Human Chorionic Gonadotropin (hCG) is a luteinizing hormone (LH) analog used in testosterone replacement therapy to stimulate natural testosterone production in the testes while preserving testicular size and fertility potential.1 Unlike direct testosterone supplementation, hCG works by mimicking the body's own signaling system — binding to LH receptors on Leydig cells and triggering endogenous testosterone synthesis from within the testes.
The FDA has not specifically approved hCG for TRT, but it's widely prescribed off-label as adjunctive therapy or monotherapy for men with secondary hypogonadism who want to maintain fertility. Brand names include Pregnyl, Novarel, and Ovidrel. It carries no DEA scheduling restrictions.
hCG is administered via subcutaneous injection using small insulin-type needles, typically 2-3 times weekly at doses ranging from 250-500 IU per injection. Most patients self-administer at home with minimal discomfort.
This treatment addresses secondary hypogonadism and low libido symptoms while offering a critical advantage over traditional testosterone therapy: it preserves the hypothalamic-pituitary-gonadal axis, maintaining sperm production and testicular function. For younger men or those planning future fertility, hCG serves as either a standalone treatment or a protective adjunct to testosterone injections.
hCG often combines with other TRT modalities for synergistic effect. Pairing it with testosterone cypionate or enanthate preserves fertility while achieving higher serum testosterone than hCG monotherapy. Some protocols add human menopausal gonadotropin (hMG) for men with persistently low sperm counts despite hCG use.
Clomiphene citrate offers an oral alternative for stimulating endogenous testosterone production, though it works via different mechanisms (blocking estrogen feedback at the pituitary) and doesn't directly target the testes like hCG.
For men prioritizing convenience over fertility, testosterone pellets or long-acting injections like testosterone undecanoate eliminate frequent dosing but suppress natural production entirely.
Related treatment options include combination protocols that use lower testosterone doses alongside hCG to minimize HPTA suppression, or adjunctive therapies like anastrozole for estrogen control and FSH for spermatogenesis support.
hCG functions as a molecular mimic of luteinizing hormone, binding to LH/hCG receptors on testicular Leydig cells and triggering a cascade of biochemical events that culminate in testosterone production.2 When the receptor activates, it stimulates adenylate cyclase, increasing cyclic AMP levels inside the cell. This amplified signal drives the conversion of cholesterol into testosterone through a multi-step enzymatic pathway.
The critical distinction from exogenous testosterone: hCG maintains intratesticular testosterone (ITT) levels at 100-200 times higher than serum concentrations — the environment necessary for spermatogenesis.3 Exogenous testosterone suppresses LH secretion from the pituitary, causing ITT to plummet by 94% within weeks. hCG bypasses this suppression by directly stimulating the testes, preserving both testosterone production and sperm development.
Pharmacokinetics and Absorption
Subcutaneous hCG exhibits rapid absorption, with peak serum levels reached within 6-12 hours post-injection. The half-life ranges from 24-36 hours due to its glycoprotein structure, which protects it from rapid enzymatic breakdown.4 Bioavailability via subcutaneous administration is 70-90% compared to intravenous, making it highly efficient for home use.
The body metabolizes hCG primarily in the liver, with renal excretion of inactive metabolites. Distribution occurs mainly in extravascular spaces, with minimal blood-brain barrier penetration.
Clinical Trial Evidence
A retrospective study of 28 men switching from exogenous testosterone to hCG monotherapy demonstrated significant testosterone increases — from 307 ng/dL to 422 ng/dL — in patients who had discontinued testosterone.5 Symptom scores stabilized, and hematocrit decreased from 45.3% to 44.2%, suggesting lower polycythemia risk compared to testosterone therapy.
Another trial of 31 hypogonadal men with baseline testosterone above 300 ng/dL reported symptomatic improvements in libido and erectile function with weekly hCG, even without biochemical testosterone changes.6 No thromboembolic events or PSA elevations occurred during follow-up.
Fertility preservation trials show that 500 IU hCG every other day alongside testosterone increased intratesticular testosterone by 26% and maintained spermatogenesis at one-year follow-up.3 Lower doses (250 IU) reduced the ITT drop from 94% to just 7%, demonstrating dose-dependent preservation of testicular function.
Efficacy rates in responsive cohorts range from 70-90% for achieving therapeutic testosterone levels (above 300-400 ng/dL) and meaningful symptom improvement.
hCG administration protocols vary based on treatment goals — monotherapy for hypogonadism versus adjunctive use with testosterone for fertility preservation.
Monotherapy Protocols
For men using hCG as the sole treatment for hypogonadism, standard dosing is 1,500-2,000 IU administered subcutaneously three times per week. Injections are typically spaced evenly (Monday/Wednesday/Friday or similar) to maintain stable hormone levels. This approach works best for younger men with secondary hypogonadism who retain testicular responsiveness.
Adjunctive Use with Testosterone
When combined with testosterone therapy to preserve fertility, lower doses are effective. The most common protocol is 250-500 IU administered 2-3 times weekly alongside standard testosterone injections. This maintains intratesticular testosterone without overwhelming estrogen conversion or causing excessive testicular stimulation.
Injection Technique
Subcutaneous injection sites include the abdomen (2 inches from the navel), outer thigh, or back of the upper arm. Rotate sites to minimize tissue irritation. Use insulin syringes (27-31 gauge, 0.5-inch needle) for minimal discomfort. Most patients report injection pain as minimal — a brief pinch comparable to insulin administration.
| Parameter | Monotherapy | Adjunctive with TRT | Notes |
|---|---|---|---|
| Starting Dose | 1,500 IU 3x/week | 250-500 IU 2-3x/week | Adjust based on testosterone response and symptoms |
| Target Trough Testosterone | 400-700 ng/dL | Maintain ITT for spermatogenesis | Check levels 48-72 hours post-injection |
| Baseline Labs | Total T, Free T, LH, FSH, Estradiol, CBC, PSA, HbA1c | Establish pre-treatment values | |
| First 6 Months Monitoring | Repeat panel at 6 weeks, 12 weeks, 6 months | Assess response and adjust dose | |
| Ongoing Monitoring | Same panel every 6-12 months once stable | Annual if no concerns; more frequent if estradiol/HCT elevated | |
| Fertility Assessment (if applicable) | Semen analysis at 6 months, annually | Track sperm count, motility, morphology | |
Dose Titration
Start conservatively with 500 IU every other day for monotherapy or 250 IU twice weekly when combined with testosterone. Recheck labs at 6 weeks. If testosterone remains below target (400 ng/dL), increase by 250-500 IU increments. For fertility preservation, prioritize maintaining testicular volume and semen parameters over hitting specific serum testosterone numbers.
Higher-BMI patients often require doses at the upper end of the range (2,000 IU 3x/week) due to increased tissue distribution and potentially reduced receptor sensitivity.
hCG is well-tolerated compared to direct testosterone supplementation, with a more favorable side effect profile — particularly regarding polycythemia and cardiovascular risk markers.5 Most adverse effects are mild and manageable with dose adjustment.
| Frequency | Mild | Moderate | Severe |
|---|---|---|---|
| Common (>10%) | Injection site soreness, minor bruising | Water retention (ankle swelling), headache | — |
| Occasional (5-10%) | Mild acne, oily skin | Gynecomastia (breast tissue growth), mood swings | — |
| Uncommon (1-5%) | Nausea, fatigue | Elevated estradiol requiring aromatase inhibitor | Severe gynecomastia requiring surgical correction |
| Rare (<1%) | — | Testicular pain, overstimulation | Thromboembolic events (no cases in trials), allergic reaction |
Gynecomastia and Estrogen Management
Breast tissue growth occurs in 5-10% of patients due to increased aromatization of testosterone to estradiol. hCG stimulates both testosterone and estrogen production in Leydig cells. If estradiol levels exceed 50 pg/mL or breast tenderness develops, adding a low-dose aromatase inhibitor (0.25-0.5 mg anastrozole twice weekly) typically resolves symptoms without eliminating estrogen's beneficial effects on bone and cardiovascular health.
Polycythemia Risk
Unlike exogenous testosterone, hCG monotherapy shows lower polycythemia incidence. One study reported a significant hematocrit decrease from 45.3% to 44.2% in men switching from testosterone to hCG.5 Still, monitor CBC every 6 months. If hematocrit exceeds 52%, consider dose reduction or therapeutic phlebotomy.
Monitoring for Adverse Effects
Track PSA at baseline and annually — any increase above 1 ng/mL per year warrants urologic evaluation. Check estradiol every 3-6 months during dose titration. Watch for signs of fluid retention (rapid weight gain, ankle swelling) and adjust sodium intake or add a mild diuretic if needed.
No thromboembolic events occurred in published trials of 28-31 patients, but theoretical risk exists with any hormone therapy that increases hematocrit or estrogen.6 Men with personal or family history of blood clots require closer monitoring.
hCG requires a prescription from a physician — typically an endocrinologist, urologist, or men's health specialist. You cannot legally obtain it over the counter or through supplement retailers. Compounding pharmacies and specialty fertility pharmacies are the primary sources, with both FDA-approved branded products and compounded formulations available.
Patient Profile
hCG suits men with secondary hypogonadism who prioritize fertility preservation, younger patients (under 40) planning future children, or those who developed testicular atrophy on traditional TRT and want to reverse it. It's also appropriate for men with baseline testosterone in the 300-400 ng/dL range who have hypogonadal symptoms but don't meet strict biochemical criteria for testosterone therapy.
It works best in men with intact testicular function — primary hypogonadism (testicular failure) shows poor response because the testes cannot respond to LH-like signals.
Insurance Coverage
Insurance coverage is inconsistent. Most plans cover branded hCG (Pregnyl, Novarel) when prescribed for documented hypogonadism with two morning testosterone readings below 300 ng/dL. Fertility preservation as an indication often faces denial, requiring appeal or out-of-pocket payment. Prior authorization typically requires diagnosis codes for secondary hypogonadism, documented symptoms, and failed conservative treatments.
Compounded hCG usually isn't covered, forcing cash payment. Some patients appeal coverage denials successfully by providing fertility preservation medical necessity letters from their provider.
Cost Breakdown
Monthly costs range from $50-150 depending on source and dose. Compounded hCG from specialty pharmacies typically costs $60-90 for a month's supply at standard dosing (500 IU 3x/week). Branded products run $100-150 per month. Telehealth TRT clinics often include hCG in bundled pricing ($150-250/month for testosterone plus hCG).
hCG is eligible for HSA/FSA reimbursement when prescribed for a diagnosed medical condition. Keep receipts and obtain a letter of medical necessity if your plan administrator requests documentation.
Access Pathways
Three main routes: in-person endocrinology or urology practices, men's health clinics specializing in TRT, and telehealth services with nationwide prescribing. Telehealth offers convenience — virtual consultation, lab order to a local Quest or LabCorp, prescription sent to a partner compounding pharmacy that ships refrigerated vials to your door.
Expect initial labs (total testosterone, free testosterone, LH, FSH, estradiol, CBC, metabolic panel, PSA) and a follow-up at 6-8 weeks to assess response before finalizing the protocol.